ARO-RAGE for Asthma

This trial tests a new inhaled treatment called ARO-RAGE to evaluate its effectiveness for individuals with mild atopic asthma, particularly after allergen exposure. The goal is to determine if ARO-RAGE can manage the late asthmatic response, which occurs when asthma symptoms flare up hours after allergen exposure. Participants will receive either ARO-RAGE or a placebo (a treatment with no active drug) to compare effects. Ideal candidates for this trial have been diagnosed with mild, stable asthma and have confirmed allergies from a skin test. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Yes, you will need to stop taking corticosteroids, immunosuppressives, anti-inflammatory medications, or any chronic medication for allergic asthma, as they can interfere with the study.

Previous studies have shown ARO-RAGE to be safe. Patients using ARO-RAGE experienced no negative effects on lung function, and the medicine primarily remained in the lungs, where it is needed, with minimal distribution to other body parts. Healthy volunteers also tolerated ARO-RAGE well, with no serious side effects reported. Overall, research suggests that the treatment is safe and well-tolerated.¹²³⁴⁵

Most treatments for asthma focus on reducing inflammation and opening airways, often using inhaled corticosteroids or bronchodilators. But ARO-RAGE works differently, targeting the receptor for advanced glycation end-products (RAGE) to potentially reduce inflammation in the lungs. This new mechanism of action could offer an alternative for patients who do not respond well to standard therapies. Researchers are excited because ARO-RAGE is administered through inhalation, directly targeting the lungs, which might lead to more efficient and rapid symptom relief compared to systemic treatments.

Research has shown that ARO-RAGE could be a helpful treatment for asthma. In studies, patients experienced up to an 88% drop in a blood marker called sRAGE, linked to inflammation in asthma. This decrease suggests that ARO-RAGE might help reduce lung inflammation associated with asthma. Additionally, the treatment significantly reduced certain genes in lung tissues, indicating it may effectively lessen asthma symptoms. These early results are promising for people with mild to moderate asthma. Participants in this trial will receive either ARO-RAGE inhalation or a placebo to further evaluate its effectiveness.¹²⁴⁵⁶